[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100332108":3},{"organization":4,"outcomesModule":7,"designInfo":21,"detailedDescription":25,"studyPopulation":26,"armGroups":27,"interventions":33,"overallOfficials":40,"centralContacts":44,"locations":53,"responsibleParty":70,"collaborators":74,"id":102,"slug":22,"hasResults":103,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":22,"eligibilityCriteria":107,"healthyVolunteers":103,"sex":108,"minAge":109,"maxAge":22,"enrollmentInfo":110,"targetDuration":22,"studyType":113,"phases":22,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":55,"whyStopped":22,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":130},{"fullName":5,"class":6},"Guangzhou 8th People's Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":17},[9],{"measure":10,"description":11,"timeFrame":12},"The rate of virus inhibition","the ratio of HIV RNA\\\u003C 50 copies\u002FmL at 12, 24 or 36 months after treatment.","36 Months",[14],{"measure":15,"description":16,"timeFrame":12},"The immunological ability","the count of CD4 cells",[18],{"measure":19,"description":20,"timeFrame":12},"The level of compliance","To explicit the number of people who have completed the treatment",{"allocation":22,"interventionModel":22,"interventionModelDescription":22,"primaryPurpose":22,"observationalModel":23,"timePerspective":24,"maskingInfo":22},null,"CASE_ONLY","PROSPECTIVE","This is an phase IV open-label, multicenter, single-arm clinical trial in. A total of 600 cases were planned to be recruited. These cases were given simplified therapy regimen of lopinavir (200mg) and ritonavir (50mg) (500mg, oral, bid ) combined with lamivudine (300mg, oral, qd. The observation duration is thirty-sixth months. Patients will be followed up before and 12, 24 and 36 months after receiving the simplified regimen, observing the viral inhibition rate and the change of CD4 cell count, the safety and patients'compliance.","Patients who are prescribed to take the simplified therapy regimen (LPV\u002Fr+ 3TC) because they are unable to tolerate the side-effect of or are not fit for the first-line free regimen in China, for example renal failure or osteoporosis, according to clinical judgment, no matter of the HIV-RNA viral loads and CD4 cell counts.",[28],{"label":29,"type":22,"description":30,"interventionNames":31},"Lpv\u002Fr+3TC","These cases were given simplified therapy regimen including lopinavir(200mg) and ritonavir(50mg)500 mg,oral,bid) combined with lamivudine (300 mg,oral,qd).",[32],"Drug: Lpv\u002Fr+3TC",[34],{"type":35,"name":29,"description":36,"armGroupLabels":37,"otherNames":38},"DRUG","It is a simplified therapy regimen study of lopinavir and ritonavir combined with lamivudine for HIV-1 infected patients in the real world of China.",[29],[39],"A simplified therapy regimen",[41],{"name":42,"affiliation":5,"role":43},"Weiping Cai, Bachelor","STUDY_CHAIR",[45,50],{"name":46,"role":47,"phone":48,"phoneExt":22,"email":49},"Linghua Li, Doctor","CONTACT","020-83710825","llheliza@126.com",{"name":42,"role":47,"phone":51,"phoneExt":22,"email":52},"020-83710816","gz8hcwp@126.com",[54],{"facility":5,"status":55,"city":56,"state":57,"zip":58,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":66,"contacts":67},"RECRUITING","Guangzhou","Guangdong","510060","China","CN",{"type":62,"coordinates":63},"Point",[64,65],113.25,23.11667,{"lat":65,"lon":64},[68,69],{"name":46,"role":47,"phone":48,"phoneExt":22,"email":49},{"name":42,"role":47,"phone":51,"phoneExt":22,"email":52},{"type":71,"investigatorFullName":72,"investigatorTitle":73,"investigatorAffiliation":5,"oldNameTitle":22,"oldOrganization":22},"PRINCIPAL_INVESTIGATOR","Linghua LI","Vice Chief physician",[75,78,80,82,84,86,88,90,92,94,96,98,100],{"name":76,"class":77},"Guiyang Public Health Clinical Center","UNKNOWN",{"name":79,"class":77},"The Third People's Hospital of Kunming",{"name":81,"class":77},"The Second People's Hospital of Nanjing",{"name":83,"class":6},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"name":85,"class":77},"The Third People's Hospital of Guilin",{"name":87,"class":77},"Guangxi Longtan hospital",{"name":89,"class":6},"The Fourth People's Hospital of Nanning",{"name":91,"class":6},"LiuZhou People's Hospital",{"name":93,"class":6},"Tianjin Second People's Hospital",{"name":95,"class":6},"Shenyang Sixth People's Hospital",{"name":97,"class":77},"The Sixth People's Hospital of Henan",{"name":99,"class":77},"The Sixth People's Hospital of Xinjiang",{"name":101,"class":77},"The Eighth People's Hospital of Xi'an","100332108",false,"NCT03603977","Simplified Treatment of Anti-retrovirus in China (C-STAR)","A Simplified Therapy Regimen Study of Lopinavir and Ritonavir Combined With Lamivudine for HIV-1 Infected Patients in the Real World of China","Inclusion Criteria:\n\n1. HIV-1 infection confirmed\n2. Agree to use simplified therapy regimen.\n3. Agree to detect CD4 count at least once per half a year\n\nExclusion Criteria:\n\n1. Have participated in HIV vaccine clinical trial or other drug trials in the past three months.\n2. Patients who could not complete the scheduled follow-up (such as weakness and poor compliance).\n3. Patients who have the history of resistance or allergy to LPV\u002Fr or 3TC.","ALL","18 Years",{"count":111,"type":112},600,"ESTIMATED","OBSERVATIONAL","To observe the efficacy and safety of simplified therapy regimen for treating with HIV-1 infected patients in Chinese real word.",[116],"HIV\u002FAIDS",[118,119,120],"Simplified Therapy Regimen","Real World Study","HIV-1-infected patients","2022-09-13",{"date":123,"type":124},"2022-09-14","ACTUAL",{"date":126,"type":124},"2017-11-01",{"date":128,"type":112},"2030-10-31",{"name":5,"class":6},1]